Cancer MoonShot 2020 is a coalition announced in January 2016 in the United States with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and community oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition (NIC). The NIC plans to design, initiate and complete randomized clinical trials in cancer patients with cancer at all stages of disease in up to 20 tumor types in as many as 20,000 patients by the year 2020. The projec

Property Value
dbo:abstract
  • Cancer MoonShot 2020 is a coalition announced in January 2016 in the United States with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and community oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition (NIC). The NIC plans to design, initiate and complete randomized clinical trials in cancer patients with cancer at all stages of disease in up to 20 tumor types in as many as 20,000 patients by the year 2020. The project's stated goal is to aggressively focus on rapidly developing new treatments for the disease. The organization attempts to rethink how cancer is tackled, using the body's own immune system and re-training it to detect and destroy the body's cancer cells. Some cancer specialists have expressed optimism that science has entered a "new era with the ability to rapidly determine the sequences of genes in tumor cells, searching for mutations that may be driving the cancer’s growth." Others call it "unrealistic.". There is also a new class of therapies that "unleash the immune system, spurring it to attack cancers." The difficulty of treating cancer has led researchers to develop more and more targeted drugs and immune therapies, with the future goal of hitting "cancers with several such treatments at once, much the way AIDS was tamed when researchers developed drugs to strike the virus at its vulnerable points.". This new form of combination therapy is needed as cancer is heterogeneous and multiple methods are needed to target multiple types of cancer. (en)
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 49087209 (xsd:integer)
dbo:wikiPageRevisionID
  • 731027185 (xsd:integer)
dbp:currentStatus
  • Active
dbp:founder
dbp:funding
  • Private & Public
dbp:keyPeople
  • Dr. Patrick Soon-Shiong
dbp:logo
dbp:missionStatement
  • To accelerate the potential of combination immunotherapies as the next generation standard of care in patients with cancer
dbp:name
  • Cancer Moonshot 2020
dbp:products
  • Cancer treatments immunotherapy
dct:subject
http://purl.org/linguistics/gold/hypernym
rdf:type
rdfs:comment
  • Cancer MoonShot 2020 is a coalition announced in January 2016 in the United States with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and community oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition (NIC). The NIC plans to design, initiate and complete randomized clinical trials in cancer patients with cancer at all stages of disease in up to 20 tumor types in as many as 20,000 patients by the year 2020. The projec (en)
rdfs:label
  • Cancer Moonshot 2020 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
is foaf:primaryTopic of